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Introduction
Staphylococcus aureus is associated with a variety of diseases in humans, including superficial infections, deep-seated infections, acute sepsis, respiratory infection and toxin-mediated illnesses. The first clone of meticillin-resistant S. aureus (MRSA) was identified in 1961. Molecular epidemiological evidence suggests MRSA has evolved on multiple occasions from lineages of meticillin-susceptible S. aureus (MSSA) isolates. Although MRSA was initially a healthcare-associated pathogen dominated by distinct lineages and often associated with multidrug resistance, the emergence of genetically distinct community-associated MRSA (CA-MRSA) infections in the last two decades has led to a significant clinical impact outside the hospital setting.
Moreover, CA-MRSA has also become established in healthcare settings and it has been suggested that these clones will replace the healthcare-associated MRSA (HA-MRSA) clones over time. In addition, CA-MRSA is slowly acquiring resistance to other antibiotics and as a result phenotypic distinctions between HA-MRSA and CA-MRSA are blurring [1] . Livestock-associated MRSA (LA-MRSA) is genetically distinct from CA-MRSA and HA-MRSA and has its main reservoir in farm animals [2] .
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A c c e p t e d M a n u s c r i p t 7 Molecular typing techniques such as multilocus sequence typing (MLST) have defined the S. aureus population structure [7] . MLST assigns isolates to a sequence type (ST) based on the allelic profile of the sequence within seven housekeeping loci. Isolates that share five of the seven alleles may be grouped together into clonal complexes (CCs) that describe lineages. MRSA commonly associated with human infections worldwide is due to a limited number of lineages including CC1, CC5, CC8 (and related ST239), CC22, CC30, CC45, CC59 and CC80 [4] . Lineages are genetically very distinct from each other with substantial variation in genes encoding for surface proteins and regulators, although they originally shared a common ancestor prior to SCCmec acquisition [8] .
The epidemiology of MRSA in the four decades following identification of the first MRSA was principally associated with spread in hospitals. A handful of dominant clones accounted for the majority of HA-MRSA worldwide, e.g. ST22 and ST36 in the UK, ST239 in Asia and Australia, and ST5 in North America, Japan and Korea.
These clones were able to establish themselves by their competitive advantage in the presence of intensive antibiotic use, most notably but not restricted to -lactams.
In the late 1980s, MRSA began to emerge in the community. CA-MRSA has evolved independently of the HA-MRSA clones. In the beginning this was mostly confined to closed communities, e.g. Australian aborigines, but around the late 1990s CA-MRSA emerged worldwide in the general population. CA-MRSA clones typically possess SCCmec type IV or V elements and are often positive for the PVL toxin. Like HA-MRSA, the distribution of the predominant clones tends to be geographically distinct:
ST80 in Europe and Northern Africa, ST59 in the Far East, ST93 and ST1 in Australia, and ST1 and ST8 in the USA. Since 2005, MRSA from animals (LA-
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A c c e p t e d M a n u s c r i p t 8 MRSA) has increasingly been recognised as a cause of human infections. LA-MRSA is predominantly due to the ST398 clone in Europe, whereas ST9/t899 dominates in Asia. ST398 and ST9 are tetracycline-resistant and are strongly associated with pig farms, although they are also found in a range of other farm animals. Like HA-MRSA and CA-MRSA, evolution of meticillin resistance appears to have occurred independently; phylogenomic analysis of representatives of the LA-MRSA CC398 population suggests that this lineage has descended from a human MSSA ST398 clone, which after a host jump acquired tetracycline and meticillin resistance. In this process the LA-MRSA lineage lost the Sa3 phage carrying the human evasion genes sak, scn and chp [9] . LA-MRSA marks a paradigm shift in the epidemiology as humans hitherto have been the dominant reservoir. Tackling of LA-MRSA requires a One Health approach with collaboration of veterinarians, farmers, doctors and environmentalists.
The epidemiological definitions for CA-MRSA, HA-MRSA and LA-MRSA (Table 1) may not be fit for purpose in future. For example, Folden et al. reported the variation in estimating the proportion of CA-MRSA infections using epidemiological definitions: use of one set of definitions classified 5% of isolates as CA-MRSA, whilst using another set led to as many as 49% of infections to be classified as CA-MRSA [10] . In order to avoid such misclassification, the US Centers for Disease Control and Prevention (CDC) has provided a definition for CA-MRSA (Table 1) [11] . However, at the same time as CA-MRSA is becoming common in the community, changes in hospital practice such as reduced length of stay, day-only admissions, and hospitalin-the-home or community hospitals make application of traditional definitions difficult as facilities traditionally available in hospitals are increasingly delivered in the [12] . Problems are also encountered when using antibiotic susceptibility pattern or traditional genetic signatures as an indicator of epidemiological origin. In the UK, ciprofloxacin susceptibility is used widely in clinical laboratories as a marker for CA-MRSA, but the resistance pattern is variable in America where levels of ciprofloxacin resistance approach 80% in some high-risk groups [13] . Similarly, PVL detection should not be used as a sole marker for CA-MRSA [14] . Genetic definitions that use the SCCmec type IV element as a marker for CA-MRSA are flawed as they potentially include the EMRSA-15 (ST22) and USA800 (ST5) clones, which are epidemiologically HA-MRSA. As the distinction between HA-MRSA and CA-MRSA becomes increasingly blurred, a classification based solely on the SCCmec type IV element is no longer helpful. Identification of markers associated with different epidemiological niches becomes valuable when combined with stable genetic markers identifying the origin of a successful clone such as clonal complex and SCCmec type.
Each MRSA clone has emerged as a result of genetic variation such as acquisition of resistance, virulence and host adaptation genes, coupled with selective pressures such as antimicrobial usage that allow it to expand in healthcare, community and animal husbandry niches. As the number and quantity of antibiotics being used increases, so does the selective pressure exerted on the S. aureus population to develop and maintain resistance. Such conditions favour horizontal transfer of novel mobile resistance elements, and consequently have the potential to drive the emergence of a new 'super bug' with a fully multidrug resistance spectrum. For Page 10 of 34 A c c e p t e d M a n u s c r i p t 10 example, gene transfer from vancomycin-resistant enterococci led to the emergence of vancomycin-resistant S. aureus (VRSA) [15] . Fortunately, the relative fitness of these isolates is thought to be compromised [16] . Also alarming is the emergence of linezolid-resistant S. aureus (LRSA) belonging to the USA300 clone possessing the cfr resistance gene. Three such isolates were identified as part of routine surveillance in the New York region of the USA [17] . An outbreak of LRSA has also been reported in Spain [18] .
In the remainder of the paper, we will further discuss the three epidemiological types of MRSA with particular reference to the contribution of genomic information to our understanding of their emergence, spread and global dissemination, virulence and antibiotic resistance. A c c e p t e d M a n u s c r i p t 11 fluoroquinolones, but occurred at a time when fluoroquinolones were used in clinical studies in the UK. In support of the importance of fluoroquinolone resistance in selecting for HA-MRSA, a decline in prescribing of fluoroquinolones in the UK has been followed by the decline of MRSA in hospitals [19, 20] .
Hospital-associated meticillin-resistant Staphylococcus aureus
Fluoroquinolone resistance is almost universal in EMRSA-15 isolates [21] . However, this lineage is also capable of carrying a variety of different genes located on MGEs that confer resistance to aminoglycosides, macrolides, chloramphenicol, trimethoprim/sulfamethoxazole, fusidic acid, mupirocin, tetracycline and antiseptics, highlighting the selection pressure placed on EMRSA-15 [20] . Evidence of how regional prescribing regimens generate regional adaptation can be found in the genetic determinants associated with clindamycin resistance. Holden et al. examined EMRSA-15 from Germany, where clindamycin use is high, and found that the majority of isolates contained multiple independent mutations to the ermC leader peptide region rendering them resistant to clindamycin as well as erythromycin. In contrast, in the UK where the use of clindamycin is limited, all EMRSA-15 ermC leader peptides were intact, therefore making these isolates susceptible to clindamycin [21] . The human EMRSA-15 epidemic has also spread into the companion animal population [22, 23] , with veterinary hospitals also being healthcare settings that may experience high levels of transmission [24] . A c c e p t e d M a n u s c r i p t 12 documented in Portugal, Singapore and Australia [25] [26] [27] . One feature that may contribute to its success is the SCCmec IV element that this clone carries, which has a lower fitness cost than the larger SCCmec elements such as SCCmec types II and III that were prevalent in earlier HA-MRSA clones [28] . In addition, some variants of CC22 HA-MRSA have acquired the PVL-associated genes, causing outbreaks among neonates in Australia [29] and the UK [30] .
Another interesting pandemic HA-MRSA clone is ST239-MRSA-III, widespread in Australian, Asian and South American hospitals. Epidemiological studies using WGS of global populations clearly showed that isolates were clustered into regional groups indicating localised evolution, but that transmission to other continents occurred sporadically [31] . There were clear associations between isolates from countries with close cultural links, such as Portugal and Brazil. There was also evidence of direct introduction of Asian isolates to Australia [32] , the UK and Denmark. However, these MRSA failed to become established in hospitals in the UK and Denmark [20] .
Other widespread HA-MRSA clones include CC5 [predominately ST5-MRSA-II (New York/Japan MRSA/USA100) and ST5-MRSA-VI (Paediatric clone)], CC8 [ST247-
and CC45 [ST45-MRSA-IV (Berlin MRSA/USA600)] [33] . The ST5 MRSA clone has been predominant in hospitals in America [34] . Data from the Active Bacterial Core Surveillance (ABCs) from the CDC indicate that USA100 (ST5) is the predominant strain type, although from 2004 onwards the more virulent type USA300 (ST8) isolates are increasingly recognised as a cause of hospital-associated bacteraemia [35] [36] [37] . Indeed, the USA300 epidemic peaked in 2004 leading to the mathematical Page 13 of 34 A c c e p t e d M a n u s c r i p t 13 predictions that the USA300 CA-MRSA strains will eventually displace the HA-MRSA strains owing to the survival advantage of the former as a result of smaller and fewer genes leading to enhanced fitness [38] . Whilst USA300 continues to be a predominant clone, there are significant regional differences in the proportion of bloodstream infections caused by USA300 clone. Jenkins et al. found that the proportion of USA300 clone ranged from 19% to 62% of the bloodstream MRSA isolates even within Denver, CO [39] . The incidence of USA300 in invasive infections has declined since the peak in 2004 [40] . Thus, whilst different countries and regions have different dominant clones, they also have different rates of MRSA infection, different prescribing practices and healthcare systems, each providing unique selective pressures that have a profound effect on strain dynamics.
Community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA)
CA-MRSA has been circulating in Europe since the 1990s [41] [42] [43] . In the beginning, the CC80 lineage predominated the epidemiological group. The CC80 clones possess the PVL-associated genes that encode the PVL toxin. Phylogeographical analysis reveals that CC80 emerged in sub-Saharan Africa in the 1980s before rapidly disseminating into Europe, most likely via coastal areas of Guinea, as a result of human migration. This imported lineage then spread throughout Europe within 10 years, followed by another secondary spread a few years later. At the time it was introduced into Europe the CC80 lineage contained the PVL-associated genes.
Genes encoding PVL were subsequently acquired as it spread across continents. In terms of resistance to antibiotics, the African ancestor lineage was generally Page 14 of 34 A c c e p t e d M a n u s c r i p t 14 susceptible except for tetracycline, whilst fusidic acid resistance was acquired following introduction into Europe where topical use of fusidic acid is widespread in some regions [44] .
The American story of CA-MRSA is strikingly different. In the USA, CA-MRSA was first documented in children during the late 1990s. The isolates belonged to a single clone, designated USA400 (belonging to CC1), and caused sepsis with pneumonia associated with high lethality. The USA400 clone has subsequently been replaced by USA300, a member of CC8, which is now the most common CA-MRSA in This appears to support the hypothesis that USA300 may be on the same trajectory as CC8-E was at one point in its evolutionary history and could in the future become multiresistant. Clade CC8-A also carries the PVL-associated genes and contains isolates that belong to the USA300 clone. In a study investigating the genomics of USA300, Uhlemann et al. found evidence for at least five different acquisitions of the lukSF-carrying prophage into the ST8 population, but only a single event into USA300 clone [47] . From their phylogenomic analysis, the authors concluded that acquisition of the lukSF-carrying prophage coincided with the acquisition of ACME and occurred between 1970 and 1993, resulting in the emergence of USA300. The USA300 clone has spread to other continents including Europe and South America [48] . The expansion of USA300 in Europe may have occurred as a single point introduction followed by spread, or by multiple introductions over a long period of time followed by limited spread on each occasion. WGS data on the French isolates reveal that following multiple introductions, the lineage has stabilised and may even decline [49] .
Another clinically relevant gene associated with USA300 clone is the msrA gene encoding resistance to macrolides and streptogramins. This gene is carried on the rep16 plasmid, and at least eight rep family plasmids have been identified within the CC8 lineage. The rep16 plasmid was acquired more recently when it replaced the rep20 plasmid typical of the older isolates within clade A [46] . A feature of CA-MRSA 
Livestock-associated meticillin-resistant Staphylococcus aureus (LA-MRSA)
Infections with LA-MRSA can occur in people who have direct contact with farm animals in factory farms (especially pig and poultry production systems). This affects, for example, farmers, veterinarians or slaughterhouse employees. MRSA was first described in animals in 1972 when it was found in a cow [57] . However, it was not until 2005 when CC398 MRSA was reported from pigs both in France and The Netherlands that livestock was shown to be an important zoonotic reservoir for MRSA. Pigs are the main reservoir for CC398, but this clone has also been found in veal calves (especially in The Netherlands and Belgium), poultry, horses and, to a lesser extent, dairy cows. In addition, CC398 has been found in pets such as dogs and cats as well as in rodents. There is a general consensus that the prevalence of CC398 is increasing rapidly worldwide. However, precise information on the true prevalence of CC398 in animals is difficult to obtain. In The Netherlands it is estimated that >80% of all farms are MRSA-positive. In Denmark, a recent Page 18 of 34 A c c e p t e d M a n u s c r i p t 18 surveillance study showed that 60-70% of all pig herds are positive, whereas in Norway only a very few farms have been found to be positive. However, in most other countries no systematic surveillance on CC398 or other types of LA-MRSA is performed in animals (the same holds true for the surveillance of these strains in humans).
Whilst CC398 MRSA is the overwhelmingly dominant lineage in livestock in Europe, CC9 MRSA is the predominant type in Southeast Asia. In addition to these two clonal complexes, a number of other MRSA lineages including CC1, CC5, CC97, CC121, CC130 and ST425 have been reported from livestock [58] . MRSA belonging to CC130 and ST425 are meticillin-resistant due to the recently described mecC gene instead of the mecA gene. The mecC gene only has ca. 70% similarity to the mecA gene [59] . As a result, molecular diagnostic assays need to encompass primers for both types. CC97, a widely disseminated human CA-MRSA type, is also interesting as it descended from bovine MSSA and has acquired SCCmec after the bovine-to-human host adaptation. This is in contrast to the livestock clade of CC398 that acquired SCCmec after jumping from humans to pigs [9, 60] . with the farm environment itself rather than through a generalised spread in the community [63] . The relative contribution of transmission via the environment or via humans in contact with pigs is unknown. However, based on knowledge of transmission of S. aureus in other settings, transmission through human-to-human contact is likely to predominate [64] .
As MRSA has been found on meat in 10-20% of samples tested on many occasions, there have been reports in the lay press on the risk of acquisition of MRSA via the food chain. The epidemiology on LA-MRSA, however, clearly shows that meat is not an important route of transmission. If it were the case, one would see a very different geospatial distribution among cases not associated with pig contact [63] . Further evidence against this route of transmission is provided by the low incidence of LA-MRSA found in slaughterhouse workers. There may be some risk of acquisition of MRSA as a result of handling of meat, rather than ingestion, but Furthermore, the greater the human carriage of LA-MRSA clones, the greater the risk that these clones will undergo adaptation enhancing human-to-human transmissibility.
Measures to counteract the expanding reservoir in pigs are thus urgently needed, as are measures to lower the bacterial burden in the farm environment. 
Application of genomics in epidemiological settings and outbreak investigations

Conclusion
The story of MRSA is one of dramatic recent success driven by the widespread use of antibiotics. Staphylococcus aureus clones have co-evolved with humans, and MRSA have emerged from the population on multiple occasions. The rapid spread of MRSA has been aided by human migration, which itself has reached a level never seen before in the history of mankind. MRSA has adapted to the environments and conditions that humans have created and where they have thrived. Clones have Page 23 of 34 A c c e p t e d M a n u s c r i p t 23 jumped from one host species to another, have amplified in the niche areas, and then gone back to colonise the population where it emerged while still retaining a strong foothold in specialised environments. There is significant overlap between clones across the traditional groups (HA-MRSA and CA-MRSA) as well as some blurring of the groups themselves as healthcare is increasingly delivered in the community. Newer technologies such as WGS will lead to a better epidemiological understanding of MRSA. Use of antibiotics in humans and livestock has given this highly adaptive species a survival advantage, as it is easily able to acquire resistance. Staphylococcus aureus has not lost its virulence either, as it continues to be a primary human pathogen with significant mortality associated with invasive disease.
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